A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer

Published:2024-09 Issue: Volume: Page:
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Zhang KeJing,Wei Juan,Zhang SheYu,Fei Liyan,Guo Lu,Liu Xueying,Ji YiShuai,Chen WenJun,Ciamponi Felipe E.,Chen WeiChang,Li MengXi,Zhai Jie,Fu Ting,Massirer Katlin B.,Yu Yang,Lupien Mathieu,Wei Yong,Arrowsmith Cheryl. H.,Wu Qin^ORCID,Tan WeiHong

Funder

Zhejiang Province Natural Science Foundation

Canadian Institutes of Health Research

National Natural Science Foundation of China

Key R&D Plan in Zhejiang Province

Publisher

Elsevier BV

Reference66 articles.

1. Pathology of triple negative breast cancer;Borri;Semin. Cancer Biol.,2021

2. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs;Bianchini;Nat. Rev. Clin. Oncol.,2022

3. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease;Bianchini;Nat. Rev. Clin. Oncol.,2016

4. Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects;Chen;JCI Insight,2023

5. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives;Schettini;Cancer Treat Rev.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP